May 17th 2024
Patients who missed their initial HCV treatment appointment had greater housing instability, transportation difficulty, and a history of medication non-adherence.
The Rise of Obesity in the US: Recognizing Gastrointestinal and Hepatic Comorbidities
October 6th 2023Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.
Study Highlights Efficacy of ALT/HDL-C Ratio as Biomarker for NAFLD
September 22nd 2023Investigators suggested an ALT/HDL-C ratio of 15.97 as a screening threshold for identifying NAFLD, noting its increased effectiveness compared to ALT, HDL-C, the aspartate aminotransferase to HDL-C ratio, and the gamma-glutamyl transferase to HDL-C ratio.
Noninvasive ABDA Score Predicts Fibrotic NASH
September 15th 2023Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.
Physical Activity, Television Viewing Linked to NAFLD Prevalence
September 13th 2023The study's findings show an association between NAFLD prevalence, physical activity, and television viewing, with higher levels of physical activity paired with lower levels of television viewing leading to a statistically significantly reduced risk of NAFLD.
Biomarker Panels Meet Criteria for Diagnostic Enrichment Qualification in Stage 1 of NIMBLE Project
September 8th 2023Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.